Industries > Pharma > Allergic Rhinitis Drugs Market Forecast 2016-2026

Allergic Rhinitis Drugs Market Forecast 2016-2026

Analysis of the Current Trend and Pipeline Opportunities in the Intranasal Antihistamines, Intranasal Corticosteroids, Oral Antihistamines, and Immunotherapy and Vaccines Markets, Including Current Products such as Patanase, Dymista, Nasonex, Allegra, and Staloral with Assessment of Key Companies in the Allergic Rhinitis Market Including GSK and Merck & Co.

PUBLISHED: 16 September 2016
PAGES: 240
PRODUCT CODE: PHA0142
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0142 Categories: ,

What can be expected from the Allergic Rhinitis Drugs Market? Which areas are going to grow at the fastest rates? This Visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects.
 
Our 240-page report provides 173 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across the all the major categories of the allergic rhinitis drugs market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2016-2026 and other analyses show you commercial prospects
Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter’s Five Forces analysis) and commercial developments.

See revenue forecasts for the leading submarkets and indications
How will submarkets perform to 2026? Our study forecasts revenues in the following Allergic Rhinitis Drugs submarkets:
• Intranasal Anthistamines
• Intranasal Corticosteroids
• Oral Antihistamines
• Immunotherapy and Vaccines

Allergic Rhinitis Drugs Market Forecast 2016-2026

See detailed profiles or revenue forecasts for some the leading products in the market
How will leading drugs perform to 2026? Our study provides detailed profiles or forecasts revenues for a number of drugs in the allergic rhinitis drugs market including:
• Patanase
• Astepro
• Astelin
• Dymista
• Nasonex
• Avamys
• Veramyst
• Flixonase
• Rhinocort
• Omnaris
• Nasacort
• Beconase
• Qnasl
• Zetonna
• Allegra
• Zyrtec
• Claritin
• Xyzal
• Allelock
• Clarinex
• Ebastel
• Talion
• Staloral
• Alutard SQ
• Grazax
• Ragwitek

See revenue forecasts for the leading international markets
How will leading national and regional markets perform to 2026? Our study forecasts revenues in national markets including products, including:
• US
• EU5 – Germany, UK, France, Italy and Spain
• China
• Japan
• India
• Russia
• Brazil

Leading companies and potential for market growth
Visiongain forecasts overall revenue for the Allergic Rhinitis Drugs Market will reach $16,500m in 2026. We predict a high revenue growth over the forecast period driven by an urbanisation, climate change, increasing patient expectations and a higher incidence of allergic rhinitis symptoms, rapid growth of emerging economies and emerging allergic rhinitis drug technologies.

Our work analyses the key companies in the market. See Visiongain’s analysis of six leading companies, including these:
• GSK
• Merck & Co
• Sanofi
• Johnson & Johnson
• ALK-Abello
• UCB
• Kyowo Hako Kirin
• Stallergenes Greer

A company profile gives you the following information where available:
• Discussion of a company’s activities and outlook
• Historic revenue, analysis and discussion of company performance
• Analysis of major products currently on the market
• Acquisitions and strategic partnerships

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect the allergic rhinitis drugs industry?
Our new report discusses issues and events affecting the allergic rhinitis drugs market. You will find discussions, including qualitative analyses:
• Highly competitive market with significant variations in different geographic regions
• Changing political and regulatory landscape changing the prospects of future products and reimbursement opportunities
• Future paradigm-shifting pipeline products
• Patent expirations and invalidations of major drugs
• Launches of new drug categories

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

Allergic Rhinitis Drugs Market Forecast 2016-2026: Analysis of the Current Trend and Pipeline Opportunities in the Intranasal Antihistamines, Intranasal Corticosteroids, Oral Antihistamines, and Immunotherapy and Vaccines Markets, Including Current Products such as Patanase, Dymista, Nasonex, Allegra, and Staloral with Assessment of Key Companies in the Allergic Rhinitis Market Including GSK and Merck & Co.
In summary, our 240-page report gives you the following knowledge:
• Revenue forecasts to 2026 for the Allergic Rhinitis Drugs market – discover the industry’s prospects, finding promising places for investments and revenues
• Revenue forecasts to 2026 for each major submarket – discover prospects for leading allergic rhinitis drugs in the following areas: intranasal corticosteroids, intranasal antihistamines, oral antihistamines, and immunotherapy and vaccines.
• Detailed profiles or revenue forecasts to 2026 for 25 of the leading products in the allergic rhinitis drugs market – discover prospects for leading allergic rhinitis drugs: Patanase, Astepro, Astelin, Dymista, Nasonex, Avamys, Veramyst, Fixonase, Rhinocort, Omnaris, Nasacort, Beconase, Qnasl, Zetonna, Allegra, Zyrtec, Claritin, Xyzal, Allelock, Clarinex, Ebastel, Talion, Staloral, Alutard SQ, Grazax, Ragwitek.
• Revenue forecasts to 2026 for eleven leading national markets and one leading regional markets – US, EU5, China, Japan, India, Russia, and Brazil.
• Assessment of eight leading companies – analysis of products, revenue, mergers & acquisitions, product type and product pipelines
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain’s study is for everybody needing commercial analyses for the over the counter medicine market and leading companies. You will find data, trends and predictions. Please order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Allergic Rhinitis Drugs Market Forecast 2016-2026


Download sample pages

Complete the form below to download your free sample pages for Allergic Rhinitis Drugs Market Forecast 2016-2026


Latest Pharma news

Visiongain Publishes Pharma Contract Manufacturing Market Report 2020-2030

Fierce competition, stringent regulations, diminishing research and development, shrinking margins, strong price pressures and patent cliffs encompass today’s drug industry.

10 August 2020

READ

Visiongain Publishes Biologics Market Report 2020-2030

Biosimilars will be changing the biologics market in the long term. But whether it does it for the better or the worse will depend on how the producers of biologics respond to their market presence.

06 August 2020

READ

Visiongain Publishes Biochips Market Report 2020-2030

Conceptually, it is clear for all stakeholders in the health care segment as well in the biotechnological sector the benefits are evident since it will improve the speed and accuracy of diagnostics or analysis.

05 August 2020

READ

Visiongain Publishes Cell and Gene Supply Chain Services and Solutions Market Report 2020-2030

With the threat of growing number of patients due to the COVID-19 infections, the supply chain trends are looking at a shift with no contact and social distancing policies.

03 August 2020

READ

Categories

Category